{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(10)"],"submitter":["Richard N"],"pubmed_abstract":["<h4>Background</h4>Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear.<h4>Aims</h4>This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world cohort.<h4>Methods</h4>From September 2022 to June 2024, all consecutive patients with refractory luminal CD treated with once daily upadacitinib 45 mg in 29 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (SFCR) at week 12, defined as a Harvey-Bradshaw Index (HBI) of < 4. Clinical response (decrease of ≥ 3 points in HBI and/or HBI < 4), clinical remission, biomarker remission, endoscopic and/or radiologic response and safety were also assessed.<h4>Results</h4>Among the 223 patients included, all were previ"],"journal":["Alimentary pharmacology & therapeutics"],"pagination":["1662-1670"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12013792"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study."],"pmcid":["PMC12013792"],"pubmed_authors":["Nancey S","Amil M","Allez M","Gilletta C","Rouilon C","Bouguen G","Abitbol V","Vidon M","Pelletier AL","Laharie D","Coffin B","Hupe M","Richard N","Amiot A","Peyrin-Biroulet L","Goutorbe F","Kwiatek S","Le Berre C","Seksik P","Nachury M","Vuitton L","Uzzan M","Altwegg R","Fumery M","Caillo L","Brixi H","Buisson A","Benezech A","GETAID"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study.","description":"<h4>Background</h4>Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear.<h4>Aims</h4>This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world cohort.<h4>Methods</h4>From September 2022 to June 2024, all consecutive patients with refractory luminal CD treated with once daily upadacitinib 45 mg in 29 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (SFCR) at week 12, defined as a Harvey-Bradshaw Index (HBI) of < 4. Clinical response (decrease of ≥ 3 points in HBI and/or HBI < 4), clinical remission, biomarker remission, endoscopic and/or radiologic response and safety were also assessed.<h4>Results</h4>Among the 223 patients included, all were previ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2025-07-07T03:10:02.013Z","creation":"2025-07-07T03:10:02.013Z"},"accession":"S-EPMC12013792","cross_references":{"pubmed":["40038887"],"doi":["10.1111/apt.70073"]}}